FDA issues warning letter to Amgen over Vectibix promotional video
The U.S. Food and Drug Administration sent a warning letter to Amgen’s chairman and CEO stating that a promotional video for Vectibix was false or misleading. The agency said the video omitted required risk information and did not disclose the drug’s full FDA‑approved indication, violating the Federal Food, Drug, and Cosmetic Act. FDA officials demanded Amgen take immediate corrective action and warned that failure to do so could lead to legal enforcement such as seizure or injunction. The letter was reported by multiple news outlets on 27 October 2026.
Why it matters
The company now faces regulatory risk that could delay or restrict Vectibix marketing, potentially impacting sales. The FDA’s threat of enforcement action adds legal uncertainty for investors.
Key facts
- 1The FDA sent a letter to Amgen’s chairman and CEO indicating the promotional video for Vectibix was false or misleading. tipranks.com
- 2The agency said the video violated the Federal Food, Drug, and Cosmetic Act by misrepresenting safety and effectiveness and omitting risk information. tipranks.com
- 3FDA demanded Amgen take immediate action to address the violations, warning that failure could result in seizure and injunction. tipranks.com
- 4A separate report noted the FDA warning letter concerned a Vectibix TV ad that misrepresented the drug’s safety and effectiveness. seekingalpha.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.